SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 95 400 KRW -2.25% Market Closed
Market Cap: 7.5T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

Relative Value

The Relative Value of one SK Biopharmaceuticals Co Ltd stock under the Base Case scenario is 32 452.45 KRW. Compared to the current market price of 95 400 KRW, SK Biopharmaceuticals Co Ltd is Overvalued by 66%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
32 452.45 KRW
Overvaluation 66%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
85
vs Industry
10
Median 3Y
19.9
Median 5Y
21.8
Industry
2.5
Forward
14.2
vs History
9
vs Industry
Median 3Y
-71.7
Median 5Y
-70.9
Industry
21.9
Forward
102.6
vs History
3
vs Industry
Median 3Y
-58
Median 5Y
-56
Industry
16.5
vs History
vs Industry
Median 3Y
-83.9
Median 5Y
-77.6
Industry
23.6
vs History
37
vs Industry
2
Median 3Y
18.8
Median 5Y
20.5
Industry
2.1
vs History
85
vs Industry
10
Median 3Y
19.7
Median 5Y
21.4
Industry
2.6
Forward
13.8
vs History
83
vs Industry
10
Median 3Y
21.8
Median 5Y
23.9
Industry
5.2
vs History
22
vs Industry
0
Median 3Y
-46.2
Median 5Y
-50.7
Industry
13.3
Forward
72
vs History
16
vs Industry
Median 3Y
-45.5
Median 5Y
-53.7
Industry
16.6
Forward
91.1
vs History
3
vs Industry
Median 3Y
-55.5
Median 5Y
-54.9
Industry
15.6
vs History
3
vs Industry
Median 3Y
-53.4
Median 5Y
-51.5
Industry
19.1
vs History
72
vs Industry
8
Median 3Y
15.8
Median 5Y
17.3
Industry
1.9

Multiples Across Competitors

Competitors Multiples
SK Biopharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
7.5T KRW 14.6 130.2 85.9 108.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
Average P/E: 44.6
130.2
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top